Charlotte's Web Holdings (CWBHF) Total Non-Current Liabilities (2020 - 2026)
Charlotte's Web Holdings (CWBHF) posted quarterly Total Non-Current Liabilities of $77.6 million for Q1 2026, up 13.37% year-over-year from $68.5 million in Q1 2025, and up 13.07% quarter-over-quarter from $68.7 million in Q4 2025.
Charlotte's Web Holdings (CWBHF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Charlotte's Web Holdings (CWBHF) has reported Total Non-Current Liabilities for 7 consecutive years, with $77.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 13.37% year-over-year to $77.6 million; the TTM figure through Mar 2026 stood at $77.6 million (up 13.37% YoY), while the FY2025 annual figure was $68.7 million, down 2.51% from the prior year.
- Total Non-Current Liabilities advanced to $77.6 million in Q1 2026 per CWBHF's latest filing, from $68.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $94.0 million in Q2 2024 and bottomed at $31.7 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $64.9 million across 5 years, with a median of $70.4 million in 2024.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities slipped 22.26% — and 2026, when it climbed 13.37%.
- Charlotte's Web Holdings' Total Non-Current Liabilities stood at $31.7 million in 2022, then soared by 131.71% to $73.3 million in 2023, then dropped by 3.99% to $70.4 million in 2024, then retreated by 2.51% to $68.7 million in 2025, then increased by 13.07% to $77.6 million in 2026.
- Business Quant data shows CWBHF's Total Non-Current Liabilities at $77.6 million in Q1 2026, $68.7 million in Q4 2025, and $63.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Charlotte's Web Holdings | 63.58 Mn | 49.59 Mn | 5.16 Mn | 12.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.07 Mn |
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 68.65 Mn |
| Sep 30, 2025 | 63.48 Mn |
| Jun 30, 2025 | 73.05 Mn |
| Mar 31, 2025 | 68.47 Mn |
| Dec 31, 2024 | 70.42 Mn |
| Sep 30, 2024 | 72.92 Mn |
| Jun 30, 2024 | 93.97 Mn |
| Mar 31, 2024 | 75.48 Mn |
| Dec 31, 2023 | 73.34 Mn |
| Sep 30, 2022 | 31.65 Mn |
| Jun 30, 2022 | 37.09 Mn |
| Mar 31, 2022 | 37.66 Mn |
| Dec 31, 2021 | 41.06 Mn |
| Dec 31, 2020 | 52.24 Mn |